Insider Trading May 15, 2026 08:17 PM

Delek US Holdings Executive Sells Stake Amid Corporate Activity and Analyst Upgrades

Insider transaction reported as Delek companies announce financial updates, strategic financing, and receive increased price targets from major investment banks.

By Avery Klein DK

Executive Vice President Robert G. Wright of Delek US Holdings sold a substantial block of company stock in mid-May 2026. This insider activity was noted alongside several positive corporate developments across the Delek group, including strong revenue beats reported by Delek US Energy Inc., and notable price target increases from Goldman Sachs and Raymond James for Delek US Holdings.

Delek US Holdings Executive Sells Stake Amid Corporate Activity and Analyst Upgrades
DK

Key Points

  • Delek US Holdings' EVP sold shares amid strong stock performance and positive analyst sentiment.
  • Delek US Energy reported a revenue beat for Q1 2026, achieving $2.65 billion against a forecast of $2.33 billion.
  • Multiple Delek entities executed strategic financial moves, including reducing term loan principal to $850 million and securing tenders worth $270.7 million.

Robert G. Wright, who serves as Executive Vice President (EVP) at Delek US Holdings, Inc. (NYSE:DK), executed a sale of company shares on May 13, 2026. Specifically, Mr. Wright disposed of 10,720 shares of the common stock. The transaction was completed at a price point of $47.07 per share, resulting in total proceeds amounting to $504,590.

This reported sale occurs against a backdrop of significant performance for Delek US Holdings' stock. The company's shares have seen an appreciation of 145% over the past year and are currently trading at $44.81.

Following this particular transaction, records indicate that Mr. Wright retains ownership of 48,148 shares of Delek US Holdings common stock. Independent analysis from InvestingPro suggests that the stock may be undervalued based on its calculated Fair Value assessment. Furthermore, internal research insights available in the comprehensive Pro Research Report predict that the company is positioned to achieve profitability within this year.


Beyond the executive transaction, recent corporate filings and financial reports paint a picture of ongoing strategic activity across Delek's various entities. Delek US Energy Inc. recently disclosed its first quarter 2026 earnings results, which displayed a mixed operational performance profile.

Financially, the company reported a loss per share of $0.98 for Q1 2026. This figure was noted to be less severe than the anticipated loss of $0.83. However, in terms of top-line revenue, Delek US Energy demonstrated a notable outperformance, recording $2.65 billion in revenue when analysts had forecasted $2.33 billion.


Simultaneously, Delek US Holdings, Inc. completed an important financial maneuver by successfully amending its term loan credit agreement. This amendment allowed the company to reduce the principal amount of its outstanding term loans down to $850 million. Another related development involved Delek Logistics Partners, LP, which secured tenders for 67.7% of its 2028 notes, totaling a value of $270.7 million.


The positive operational and financial developments have been acknowledged by major investment banking firms. Goldman Sachs, for instance, upgraded its price target on Delek US Holdings to $57 from the previous estimate of $55. This revision was attributed to observed cost-cutting initiatives and other strategic improvements within the company. Similarly, Raymond James increased its price target to $59, up from $54. The rationale provided by Raymond James cited a favorable refining outlook coupled with operational advancements.

These collective developments highlight ongoing strategic execution and financial refinement across the group of Delek companies, encompassing both internal governance actions and external market validation through analyst revisions.

Risks

  • The reported loss per share of $0.98 for Delek US Energy in Q1 2026 indicates ongoing profitability challenges, despite the revenue beat.
  • While analyst targets were raised due to cost-cutting and operational improvements, the underlying market valuation remains subject to these strategic execution efforts.
  • The current stock price of $44.81 is noted against a significant one-year gain of 145%, suggesting high volatility or speculative interest.

More from Insider Trading

Director Sale and Recent Earnings Surge at Trio-Tech International May 15, 2026 Insider Activity and Recent Financing Boost Confidence in Apogee Therapeutics May 15, 2026 Wheels Up CSO Sells Shares Amid Company Modernization and Financial Developments May 15, 2026 Insider Activity at Oruka Therapeutics Highlights Executive Stock Transactions Amid Clinical Progress May 15, 2026 Director Sales at Trio-Tech International Highlight Recent Insider Transactions and Company Developments May 15, 2026